Test January-February 2018 Feature Article
One of the most common clinical problems that hematologists deal with is diagnosis and management of patients with prolonged, excessive, or unusual bleeding. As a pediat
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
Dr. Moss evaluates a case that requires CAR-T cell therapy and discusses practical issues hematologists should be aware of during introduction of the treatment.
Dr. Hoggatt and Dr. George Daley discuss efforts to grow hematopoietic stem cells to care for patients with diseases treatable with bone marrow transplantation.
September/October 2017 Volume 14, Issue 5
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson discusses ASH's role in health care reform.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.
On July 13, 2017, the U.S. Senate released an updated
version of the Better Care Reconciliation Act (BCRA), legislation to repeal
large provisions of the Affordable Care Act (ACA).
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology